MTOR and Stroke: Furthermore, an in-depth study by Sun et al. demonstrated that the pretreatment of human umbilical cord mesenchymal stem cells (HUMSCs) with VX-765 improved cell survival during transplantation treatment by upregulating autophagy via the AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signaling pathway, thus ameliorating inflammatory responses, inhibiting apoptosis, and reducing infarct volume in HUMSC-transplanted models of stroke [56].